Literature DB >> 30116974

Doing it All - How Families are Reshaping Rare Disease Research.

Sean Ekins1,2, Ethan O Perlstein3.   

Abstract

The face of rare disease drug discovery and development is changing right before our eyes. The outliers of the past were the plucky parents who summoned up the courage to try to treat their children against all odds. Think of the rare disease focused movies 'Lorenzo's Oil' and 'Extraordinary Measures' but now accelerated to develop treatments even quicker. Parents, patient advocates and their collaborators are now capable of doing it all themselves. We think this will have profound implications for everyone from the incumbent rare disease foundations that have held sway for decades to the multibillion dollar rare disease market, BioPharma companies, VCs and angel investors that inhabit this space. The repercussions of this disruption will no doubt impact healthcare in general and ultimately influence how we develop treatments for major diseases as well. We present several lines of evidence for our viewpoint from our personal experiences interacting with many rare disease families and patient advocates in recent years.

Entities:  

Keywords:  disruption; drug discovery; machine learning; multiple sulfatase deficiency; rare diseases

Mesh:

Year:  2018        PMID: 30116974      PMCID: PMC6159905          DOI: 10.1007/s11095-018-2481-7

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  9 in total

1.  Identification of drug modulators targeting gene-dosage disease CMT1A.

Authors:  Sung-Wook Jang; Camila Lopez-Anido; Ryan MacArthur; John Svaren; James Inglese
Journal:  ACS Chem Biol       Date:  2012-05-02       Impact factor: 5.100

2.  Open Source Bayesian Models. 2. Mining a "Big Dataset" To Create and Validate Models with ChEMBL.

Authors:  Alex M Clark; Sean Ekins
Journal:  J Chem Inf Model       Date:  2015-06-03       Impact factor: 4.956

3.  Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis.

Authors:  Shunmoogum A Patten; Dina Aggad; Jose Martinez; Elsa Tremblay; Janet Petrillo; Gary Ab Armstrong; Alexandre La Fontaine; Claudia Maios; Meijiang Liao; Sorana Ciura; Xiao-Yan Wen; Victor Rafuse; Justin Ichida; Lorne Zinman; Jean-Pierre Julien; Edor Kabashi; Richard Robitaille; Lawrence Korngut; J Alexander Parker; Pierre Drapeau
Journal:  JCI Insight       Date:  2017-11-16

4.  Comparing and Validating Machine Learning Models for Mycobacterium tuberculosis Drug Discovery.

Authors:  Thomas Lane; Daniel P Russo; Kimberley M Zorn; Alex M Clark; Alexandru Korotcov; Valery Tkachenko; Robert C Reynolds; Alexander L Perryman; Joel S Freundlich; Sean Ekins
Journal:  Mol Pharm       Date:  2018-04-26       Impact factor: 4.939

5.  Industrializing rare disease therapy discovery and development.

Authors:  Sean Ekins
Journal:  Nat Biotechnol       Date:  2017-02-08       Impact factor: 54.908

6.  Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme.

Authors:  Thomas Dierks; Bernhard Schmidt; Ljudmila V Borissenko; Jianhe Peng; Andrea Preusser; Malaiyalam Mariappan; Kurt von Figura
Journal:  Cell       Date:  2003-05-16       Impact factor: 41.582

7.  The gene for the peripheral myelin protein PMP-22 is a candidate for Charcot-Marie-Tooth disease type 1A.

Authors:  P I Patel; B B Roa; A A Welcher; R Schoener-Scott; B J Trask; L Pentao; G J Snipes; C A Garcia; U Francke; E M Shooter; J R Lupski; U Suter
Journal:  Nat Genet       Date:  1992-06       Impact factor: 38.330

8.  A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment.

Authors:  Jonas Mandel; Viviane Bertrand; Philippe Lehert; Shahram Attarian; Laurent Magy; Joëlle Micallef; Ilya Chumakov; Catherine Scart-Grès; Mickael Guedj; Daniel Cohen
Journal:  Orphanet J Rare Dis       Date:  2015-06-13       Impact factor: 4.123

9.  Genome editing-enabled HTS assays expand drug target pathways for Charcot-Marie-tooth disease.

Authors:  James Inglese; Patricia Dranchak; John J Moran; Sung-Wook Jang; Rajini Srinivasan; Yolanda Santiago; Lei Zhang; Rajarshi Guha; Natalia Martinez; Ryan MacArthur; Gregory J Cost; John Svaren
Journal:  ACS Chem Biol       Date:  2014-09-16       Impact factor: 5.100

  9 in total
  4 in total

1.  Exploiting machine learning for end-to-end drug discovery and development.

Authors:  Sean Ekins; Ana C Puhl; Kimberley M Zorn; Thomas R Lane; Daniel P Russo; Jennifer J Klein; Anthony J Hickey; Alex M Clark
Journal:  Nat Mater       Date:  2019-04-18       Impact factor: 43.841

Review 2.  Knowledge-based approaches to drug discovery for rare diseases.

Authors:  Vinicius M Alves; Daniel Korn; Vera Pervitsky; Andrew Thieme; Stephen J Capuzzi; Nancy Baker; Rada Chirkova; Sean Ekins; Eugene N Muratov; Anthony Hickey; Alexander Tropsha
Journal:  Drug Discov Today       Date:  2021-10-27       Impact factor: 8.369

Review 3.  Epidemiological challenges in pandemic coronavirus disease (COVID-19): Role of artificial intelligence.

Authors:  Abhijit Dasgupta; Abhisek Bakshi; Srijani Mukherjee; Kuntal Das; Soumyajeet Talukdar; Pratyayee Chatterjee; Sagnik Mondal; Puspita Das; Subhrojit Ghosh; Archisman Som; Pritha Roy; Rima Kundu; Akash Sarkar; Arnab Biswas; Karnelia Paul; Sujit Basak; Krishnendu Manna; Chinmay Saha; Satinath Mukhopadhyay; Nitai P Bhattacharyya; Rajat K De
Journal:  Wiley Interdiscip Rev Data Min Knowl Discov       Date:  2022-06-28

4.  Use of the movie "Lorenzo's Oil" for didactic purposes in neuroscience and others health fields.

Authors:  Lauana Lopes Gonçalves; Tales Alexandre Aversi-Ferreira
Journal:  Dement Neuropsychol       Date:  2020 Jan-Mar
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.